tailieunhanh - Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Current evidence suggests that patients with Luminal A early breast cancer can skip chemotherapy or extended endocrine therapy, but immunohistochemistry-based biomarker analysis for St Gallen subtyping may not be reproducible. We asked whether RT-qPCR can be used instead to address this clinical question. | Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor ER positive human epidermal growth factor receptor 2 HER2 negative breast cancer upon five years of endocrine therapy

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN